Effect of Antigenic Heterogeneity on the Efficacy of Enhanced Delivery of Antibody-targeted Chemotherapy in A Human Lung Cancer Intracerebral Xenograft Model in Rats

Neurosurgery

Volumn 53, Issue 6, 2003, Pages 1406-1413

  Neuwelt, Edward A ^a,b   Thrun, Lori A ^b   Walker Rosenfeld, Shannan ^c   Cave, Andrew T ^c   Muldoon, Leslie L ^c   Amar, Arun P ^d   Glick, Roberta P ^d   Lichtor, Terry ^d  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d NONE

Author keywords

Blood brain barrier; Brain tumor; Doxorubicin; Immunoconjugate

Indexed keywords

ALLOANTIGEN; ANTIBODY CONJUGATE; DOXORUBICIN; LEWIS Y ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SGN 15; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD GROUP LEWIS SYSTEM; BRAIN CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL HETEROGENEITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG RELEASE; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; LOW DRUG DOSE; LUNG SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0345374596     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000093428.35072.F0     Document Type: Article

References (37)

1. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens R, Kristjansen P, Johnson B, Ueoka H, Wagner H, Aisner J: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission: Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476-484, 1999.
2. Braslawsky GR, Kadow K, Knipe J, McGoff K, Edson M, Kaneko T, Greenfield R: Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity. Cancer Immunol Immunother 33:367-374, 1991.
3. Cheng TL, Wei SL, Chen BM, Chern JW, Wu MF, Liu PW, Roffler SR: Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Br J Cancer 79:1378-1385, 1999.
4. Crossen JR, Garwood A, Glatstein E, Neuwelt EA: Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation induced encephalopathy. J Clin Oncol 12:627-642, 1994.
5. Dahlborg SA, Henner WD, Crossen JR, Tableman M, Perrillo A, Braziel R, Neuwelt EA: Non-AIDS primary CNS lymphoma: The first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2:166-174, 1996.
6. Denning C, Pitts JD: Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 8:1825-1835, 1997.
7. Denny WA, Wilson WR: The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. J Pharm Pharmacol 50:387-394, 1998.
8. Dilber MS, Abedi MR, Christensson B, Bjorkstrand B, Kidder GM, Naus CC, Gahrton G, Smith CI: Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 57:1523-1528, 1997.
9. Doolittle ND, Abrey LE, Ferrari N, Hall WA, Laws ER Jr, McLendon RE, Muldoon LL, Peereboom D, Peterson DR, Reynolds CP, Senter P, Neuwelt EA: Targeted delivery in primary and metastatic brain tumors: Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Clin Cancer Res 8:1702-1709, 2002.
10. Doolittle ND, Miner ME, Hall WA, Siegal T, Hanson EJ, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, Neuwelt EA: Safety and efficacy of a multi-center study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of malignant brain tumors. Cancer 88:637-647, 2000.
11. Elliott PJ, Hayward NJ, Dean RL, Blunt DG, Bartus RT: Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res 56:3998-4005, 1996.
12. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN: The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274-5283, 1993.
13. Groothuis DR: The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro-oncology 2:45-59, 2000.
14. Guillemard V, Saragovi HU: Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res 61:694-699, 2001.
15. Hellstrom I, Hellstrom KE, Senter PD: Development and activities of the BR96-doxorubicin immunoconjugate. Methods Mol Biol 166:3-16, 2001.
16. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50:814-819, 1990.
17. King HD, Yurgaitis D, Willner D, Firestone RA, Yang MB, Lasch SJ, Hellström KE, Trail PA: Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates. Bioconjug Chem 10:279-288, 1999.
18. Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA: Association of total dose intensity of chemotherapy in primary CNS lymphoma (human non-AIDS) and survival. Neurosurgery 48:1033-1041, 2000.
19. Kroll RA, Neuwelt EA: Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery 42:1083-1100, 1998.
20. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Fiamengo SA, Neuwelt EA: Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: A comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery 43:879-889, 1998.
21. Matsukado K, Inamura T, Nakano S, Fukui M, Bartus RT, Black KL: Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 39:125-134, 1996.
22. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA: Cognitive outcomes and long-term follow-up after enhanced chemotherapy delivery for primary central nervous system lymphomas. Neurosurgery 46:51-61, 2000.
23. McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD: Glioma-associated antigen expression in oligodendroglial neoplasms: Tenascin and epidermal growth factor receptor. J Histochem Cytochem 48:1103-1110, 2000.
24. Mosure KW, Henderson AJ, Klunk LJ, Knipe JO: Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Cancer Chemother Pharmacol 40:251-258, 1997.
25. Neuwelt EA, Barnett P, McCormick CI, Remsen LG, Kroll RA, Sexton G: Differential permeability of a human brain tumor xenograft in the nude rat: The impact of tumor size and method of administration on optimizing delivery of biologically diverse agents. Clin Cancer Res 4:1549-1556, 1998.
26. Neuwelt EA, Glasberg M, Frenkel E, Barnett P: Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: Neuropathological studies. Ann Neurol 14:316-324, 1983.
27. Remsen LG, Marquez C, Garcia R, Thrun L, Neuwelt EA: Efficacy and toxicity after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung xenograft model. Int J Radiat Oncol Biol Phys 51:1045-1049, 2001.
28. 2, and other factors on osmotic blood-brain barrier disruption in rats with brain xenografts. Anesth Analg 88:559-567, 1999.
29. Remsen LG, Trail PA, Hellstrom I, Hellstrom KE, Neuwelt EA: Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 46:704-709, 2000.
30. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, Daniel CR, LeBherz D, Brewer H, Onetto N, LoBuglio AF: Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol 18:2282-2292, 2000.
31. Senter PD, Springer CJ: Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev 53:247-264, 2001.
32. Sinha AA, Quast BJ, Reddy PK, Elson MK, Wilson MJ: Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2′ -deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Anticancer Res 19:893-902, 1999.
33. Sjogren HO, Isaksson M, Willner D, Hellstrom I, Hellstrom KE, Trail PA: Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res 57:4530-4536, 1997.
34. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W: Randomized Phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17:478-484, 1999.
35. Trail PA, Bianchi AB: Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol 11:584-588, 1999.
36. Trail PA, Willner D, Bianchi AB, Henderson AJ, Trail-Smith MD, Girit E, Lasch S, Hellstrom I, Hellstrom KE: Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. Clin Cancer Res 5:3632-3638, 1999.
37. Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, King D, Zoeckler ME, Braslawsky GR: Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res 52:5693-5700, 1992.